Veerhealth Care

Veerhealth Care

18.43
+0.17
(0.93%)
ann
There are new updates from the company20 hours ago
Viewcross
right
Market Cap
36.84 Cr
EPS
0.20
PE Ratio
70.23
Dividend Yield
0.00 %
Industry
Healthcare
52 Week High
24.30
52 Week Low
9.29
PB Ratio
1.64
Debt to Equity
0.11
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Veerhealth Care Limited received new orders worth Rs 0.45 crores from a US customer for oral care products. The order involves 2 x 40 FT FCL containers for Drug OTC range products and must be executed within 30 days. The customer's identity remains undisclosed due to a Non-Disclosure Agreement. The company expects these orders to play a major role in boosting its export business in the US market. The transaction does not involve related party dealings or promoter group interests.
positive
Veerhealth Care Reports 112.40% Revenue Growth to ₹5.14 Crore in Q1 FY26Aug 13, 2025
Veerhealth Care Limited reported total income of ₹5.14 crore for Q1 FY26, marking 112.40% year-over-year growth. EBITDA reached ₹0.62 crore with 82.35% growth and 12.06% margin. Net profit grew 104.08% to ₹0.24 crore with 4.67% margin. The company received USFDA clearance for drug exports to the USA and completed formalities for medical device exports. It secured regulatory approval from Gujarat's Food and Drug Authority for personal care manufacturing and received its first commercial order worth ₹0.48 crore. The company dispatched 3 export shipments to the US and received a ₹0.74 crore export order for oral care products. Ayuveer products were onboarded on Myntra, joining Amazon, Flipkart, Nykaa, Glowroad, and Jiomart. Production commenced at a new facility with in-house plastic molding capabilities. Managing Director Bhavin Shah expects total revenues of ₹30-35 crores with 10% PAT for FY 2025-26, and projects reaching ₹100 crores revenue with 10% PAT within 24-36 months.
positive
Veerhealth Care Limited Reports Q1 FY2026 Results and Schedules 33rd AGMAug 12, 2025
Veerhealth Care Limited's Board approved unaudited financial results for the quarter ended June 30, 2025. The company reported revenue from operations of ₹448.52 lakhs, compared to ₹206.45 lakhs in the same quarter last year and ₹562.00 lakhs in the previous quarter. Total revenue reached ₹513.56 lakhs with other income of ₹65.04 lakhs. The company posted a profit of ₹24.06 lakhs for the quarter, recovering from a loss of ₹9.93 lakhs in the previous quarter. Basic earnings per share stood at ₹0.12. The Board also approved the Director's Report for the financial year ending March 31, 2025, and scheduled the 33rd Annual General Meeting for September 30, 2025, at 11:30 AM in Mumbai. The company operates in a single segment of Healthcare Pharma Products.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,637.40
#1 3,92,867.11
33.89
#1 54,729.00
9.71
#1 10,980
-19.84
49.41
6,071.50
1,61,179.25
69.65
9,712.00
18.67
2,191
26.74
46.47
1,568.10
1,26,656.66
23.36
28,409.50
7.12
5,291
9.88
51.03
3,551.00
1,20,181.98
59.39
11,539.40
6.99
1,911
19.91
42.91
1,313.70
1,09,637.60
#1 19.26
33,741.20
16.73
5,725
1.26
60.11
2,598.90
1,07,264.07
56.09
12,744.20
#1 20.90
2,007
-18.14
53.12
1,029.90
1,03,632.04
22.34
23,511.00
18.55
4,615
2.60
62.88
2,030.30
92,722.88
25.08
22,909.50
13.74
3,306
#1 51.64
68.18
31,150.00
66,191.58
45.28
6,684.70
9.64
1,414
11.55
39.16
5,489.00
65,629.23
28.79
13,458.30
3.70
2,216
21.39
70.33
Forecast
Actual
Growth Rate
Revenue Growth
0.69 %
Net Income Growth
-75.00 %
Cash Flow Change
-113.45 %
ROE
-74.80 %
ROCE
10.41 %
EBITDA Margin (Avg.)
14.18 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
2
3
3
6
6
12
12
11
15
15
18
21
Expenses
2
2
2
5
6
11
11
10
13
13
16
19
EBITDA
0
0
0
1
1
1
1
1
2
2
2
2
Operating Profit %
-12 %
-1 %
-19 %
-2 %
7 %
6 %
1 %
-9 %
4 %
5 %
3 %
3 %
Depreciation
0
0
0
0
0
0
1
1
1
1
1
1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
0
0
0
0
0
1
1
0
1
1
1
1
Tax
0
0
0
0
0
0
0
0
-1
1
0
-0
Net Profit
0
0
0
0
0
0
0
-0
2
0
0
1
EPS in ₹
0.01
0.00
0.03
0.20
0.23
0.46
0.55
-0.11
1.52
0.21
0.20
0.30

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
14
14
13
15
16
18
19
20
25
28
34
Fixed Assets
2
3
3
6
6
10
10
11
12
12
20
Current Assets
8
7
8
7
3
6
7
6
10
14
11
Capital Work in Progress
0
0
0
0
2
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
Other Assets
12
11
11
9
9
9
9
10
13
16
14
Total Liabilities
14
14
13
15
16
18
19
20
25
28
34
Current Liabilities
1
1
-0
1
3
2
2
3
1
3
4
Non Current Liabilities
1
1
1
0
0
3
3
4
3
4
8
Total Equity
13
13
13
13
13
14
14
14
21
22
22
Reserve & Surplus
6
6
6
6
6
7
7
7
11
2
2
Share Capital
7
7
7
7
7
7
7
7
10
20
20

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
0
0
-0
0
0
-0
0
0
3
-3
1
Investing Activities
4
0
-0
-3
-2
-2
-0
-1
-2
-0
-8
Operating Activities
-4
0
2
2
2
-0
1
2
-1
3
-0
Financing Activities
0
0
-1
1
0
2
-1
-0
6
-6
10

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Promoter
41.92 %
41.92 %
41.93 %
41.93 %
42.34 %
44.31 %
44.36 %
44.36 %
30.76 %
30.76 %
30.76 %
30.76 %
30.41 %
30.41 %
30.41 %
30.41 %
31.50 %
31.50 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
48.78 %
48.53 %
48.11 %
47.50 %
47.42 %
44.95 %
37.12 %
47.81 %
55.14 %
58.28 %
56.23 %
56.80 %
60.05 %
59.25 %
58.57 %
58.53 %
58.35 %
57.92 %
Others
9.29 %
9.55 %
9.96 %
10.57 %
10.24 %
10.73 %
18.52 %
7.83 %
14.10 %
10.96 %
13.01 %
12.44 %
9.54 %
10.33 %
11.02 %
11.06 %
10.15 %
10.58 %
No of Share Holders
3,528
3,517
3,483
3,462
3,642
3,566
3,589
3,655
3,605
3,616
6,195
6,874
10,991
10,255
11,489
11,469
11,390
11,011

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2025 21.94 18.26
22 Sept 2023 BONUS Bonus
1:1
22 Sept 2023 40.72 41.24
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 22.37 22.09
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 19.97 18.24
12 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Feb 2025 18.51 17.21
30 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 May 2025 13.19 15.21
12 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
12 Aug 2025 22.13 21.94

Announcements

Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order20 hours ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 05, 2025
Reg. 34 (1) Annual Report.Aug 22, 2025
Shareholder Meeting - AGM On September 30 2025Aug 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 22, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderAug 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 13, 2025
Results-Financial Results For June 30 2025Aug 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 06, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderAug 05, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 04, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter Ended 30Th June 2025.Aug 01, 2025
UpdatesJul 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 25, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 23, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 22, 2025
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJul 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 09, 2025
Announcement Under Regulation 30 (LODR) - Contract Manufacturing Agreement With Leading Marketplace CompanyJul 07, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Closure of Trading WindowJun 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 17, 2025
Announcement Under Regulation 30 (LODR) - "Ayuveer" Products Now Available On Myntra For PurchaseJun 16, 2025
Announcement Under Regulation 30 (LODR) - Appointment Of Internal And Secretarial AuditorMay 30, 2025
Results-Financial Results For March 31 2025May 30, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 30, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 22, 2025
Board Meeting Intimation for Consideration And Approval Of Audited Financial Results Of The Company For The Quarter And Financial Year Ended 31St March 2025 And Recommendation Of Dividend If Any.May 21, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
Announcement Under Regulation 30 (LODR) - Successful Closure Of USFDA Inspection Under 21 CFR 20.64(D)(3)May 16, 2025
Compliances-Compliance Certificate For The Period Ended March 31 2025Apr 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2025
Closure of Trading WindowMar 26, 2025
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Mar 07, 2025
Integrated Filing (Financial)Feb 12, 2025
Results-Financial Results For December 31 2024Feb 12, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 12, 2025
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results Of The Company For The Quarter And Nine Months Ended 31St December 2024Feb 04, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Closure of Trading WindowDec 28, 2024
Announcement Under Regulation 30 (LODR) - Introduction Of New Division In Hospital Care SegmentDec 18, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationDec 14, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 12, 2024
Announcement Under Regulation 30 (LODR) - Closure Of Assessment By USFDA Of Form 4003 - FDA Pre-Inspection Records RequestDec 11, 2024
Board Meeting Outcome for Outcome Of Board Meeting For Approval Of Rights Issue Draft Letter Of OfferNov 26, 2024
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 16, 2024
Results-Financial Results For September 30, 2024Nov 14, 2024
Board Meeting Outcome for Outcome Of Board MeetingNov 14, 2024
Board Meeting Intimation for Consider And Approval Of Unaudited Financial Results Of The Company For The Quarter And Half Year Ended 30Th September, 2024.Nov 06, 2024

Technical Indicators

RSI(14)
Neutral
26.86
ATR(14)
Less Volatile
1.02
STOCH(9,6)
Neutral
21.21
STOCH RSI(14)
Neutral
20.36
MACD(12,26)
Bearish
-0.11
ADX(14)
Weak Trend
19.20
UO(9)
Bearish
37.19
ROC(12)
Downtrend And Accelerating
-6.31
WillR(14)
Oversold
-90.37